aTyr Pharma, Inc. (LIFE) Social Stream
ATYR PHARMA INC (LIFE) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering LIFE.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-12 | 5 | $22 | $18 | $19.666 | $1.5 | 1211.07% |
| 2022-03-15 | 5 | $22 | $11 | $18.5 | $1.5 | 1133.33% |
| 2022-04-12 | 5 | $22 | $11 | $18.666 | $1.5 | 1144.4% |
| 2022-05-11 | 5 | $22 | $11 | $18.8 | $1.5 | 1153.33% |
| 2022-05-18 | 5 | $22 | $11 | $17.2 | $1.5 | 1046.67% |
| 2022-08-16 | 4 | $35 | $11 | $22.25 | $1.5 | 1383.33% |
| 2022-10-07 | 4 | $35 | $14 | $24 | $1.5 | 1500% |
| 2022-10-11 | 4 | $35 | $14 | $24.666 | $1.5 | 1544.4% |
| 2022-11-11 | 3 | $35 | $14 | $24.666 | $1.5 | 1544.4% |
| 2023-02-07 | 3 | $35 | $14 | $22 | $1.5 | 1366.67% |
| 2023-02-14 | 3 | $35 | $9 | $20.333 | $1.5 | 1255.53% |
| 2023-03-02 | 4 | $35 | $9 | $20 | $1.5 | 1233.33% |
| 2023-03-10 | 4 | $35 | $9 | $17.8 | $1.5 | 1086.67% |
| 2023-05-10 | 5 | $35 | $9 | $18.6 | $1.5 | 1140% |
| 2023-08-10 | 5 | $35 | $9 | $20.75 | $1.5 | 1283.33% |
| 2023-11-10 | 4 | $35 | $19 | $24.666 | $1.5 | 1544.4% |
The Trend in the Analyst Price Target
LIFE's average price target has moved up $9 over the prior 31 months.
LIFE reports an average of 985.94% for its upside potential over the past 39 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-07 | 3 | 35 | 14 | 22.000 | 2.47 | 790.69% |
| 2023-07-21 | 5 | 35 | 9 | 20.750 | 2.07 | 902.42% |
| 2023-08-10 | 5 | 35 | 9 | 20.750 | 1.96 | 958.67% |
| 2023-08-10 | 5 | 35 | 19 | 24.666 | 1.96 | 1158.47% |
| 2023-11-10 | 4 | 35 | 19 | 24.666 | 1.12 | 2102.32% |
LIFE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.75 | 2 | 1 | 1 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 31 weeks, LIFE's average broker recommendation rating worsened by 0.55.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, ATYR PHARMA INC's upside potential (average analyst target price relative to current price) is higher than 1954.94% of them.
- LIFE has a lower variance in analysts' estimates than -1530.96% of all US stocks.
- In terms of how ATYR PHARMA INC fares relative to Healthcare stocks, note that its number of analysts covering the stock is higher than 393.6% of that group.
- ATYR PHARMA INC's average analyst price target is higher than 702.94% of Healthcare stocks.
In the Pharmaceutical Products industry, DBVT, EIGR, and OCGN are the three stocks most similar to ATYR PHARMA INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding LIFE using the data that counts. Try POWR Ratings for free.